Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin
Axel Bidon‐Chanal(Universitat de Barcelona), Miguel Medina(Baptist Hospital of Miami), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Daniel I. Pérez(Cedars-Sinai Medical Center), Ana María de Caso Fuertes, F. Javier Luque(Universidad Complutense de Madrid), D. A. Alonso(Neuron BioPharma (Spain))
Cited by 73
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies
|American Journal Of Pathology|2002|331